Harmony Biosciences (NASDAQ:HRMY) Price Target Cut to $28.00 by Analysts at Bank of America

Harmony Biosciences (NASDAQ:HRMY) had its target price reduced by Bank of America from $32.00 to $28.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have an underperform rating on the stock.

Several other analysts also recently issued reports on HRMY. Truist Financial downgraded Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Monday. Oppenheimer reaffirmed an “outperform” rating and set a $62.00 target price on shares of Harmony Biosciences in a research report on Monday, November 24th. UBS Group downgraded Harmony Biosciences from a “buy” rating to a “neutral” rating and increased their price target for the company from $43.00 to $46.00 in a report on Wednesday, February 11th. HC Wainwright reissued a “buy” rating on shares of Harmony Biosciences in a research report on Wednesday, December 3rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $42.00 price objective on shares of Harmony Biosciences in a research note on Monday, November 24th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $42.67.

Harmony Biosciences Stock Performance

Shares of HRMY opened at $28.19 on Wednesday. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of 10.40, a price-to-earnings-growth ratio of 0.26 and a beta of 0.84. The company’s fifty day moving average is $36.36 and its 200-day moving average is $34.15. The company has a quick ratio of 3.72, a current ratio of 3.60 and a debt-to-equity ratio of 0.17. Harmony Biosciences has a 12 month low of $25.52 and a 12 month high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.38 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.46). The business had revenue of $243.78 million during the quarter, compared to analyst estimates of $240.04 million. Harmony Biosciences had a net margin of 18.29% and a return on equity of 19.86%. The firm’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.85 EPS. Equities analysts expect that Harmony Biosciences will post 2.43 EPS for the current fiscal year.

Insider Activity at Harmony Biosciences

In other news, CEO Jeffrey M. Dayno sold 25,933 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $40.11, for a total value of $1,040,172.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Sandip Kapadia sold 20,961 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $35.92, for a total transaction of $752,919.12. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 50,640 shares of company stock worth $1,932,256. Company insiders own 23.60% of the company’s stock.

Institutional Trading of Harmony Biosciences

A number of hedge funds have recently bought and sold shares of HRMY. Amundi increased its holdings in shares of Harmony Biosciences by 115.6% during the 1st quarter. Amundi now owns 39,668 shares of the company’s stock worth $1,229,000 after purchasing an additional 21,266 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Harmony Biosciences by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock valued at $752,000 after buying an additional 984 shares during the period. Empowered Funds LLC bought a new stake in shares of Harmony Biosciences in the first quarter valued at about $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Harmony Biosciences by 53.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock worth $3,166,000 after buying an additional 33,058 shares in the last quarter. Finally, AlphaQuest LLC increased its stake in Harmony Biosciences by 340.2% during the second quarter. AlphaQuest LLC now owns 17,601 shares of the company’s stock valued at $556,000 after acquiring an additional 13,603 shares during the period. 86.23% of the stock is owned by institutional investors.

Trending Headlines about Harmony Biosciences

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and $55 price target (about +95% from the current level), a clear bullish endorsement that could attract buyers. HC Wainwright rating
• Positive Sentiment: Needham cut its target slightly (from $46 to $44) but kept a “buy” rating, leaving substantial upside (~+56%) — another vote of confidence from a sell-side shop. Needham rating
• Positive Sentiment: Company results show continuing commercial strength: Q4 revenue of $243.8M (+21% y/y) and full-year 2025 product revenue of $868.5M; management reiterated ~>$1B revenue guidance and expects WAKIX revenue around $1.0–$1.04B in 2026 — growth signals that support a longer-term bullish case. BusinessWire release
• Neutral Sentiment: Q4 EPS missed Street expectations ($0.38 vs. $0.84 est.), creating short-term earnings disappointment even as revenue beat; investors will be parsing whether the EPS miss reflects one-offs or structural margin pressure. Zacks earnings note
• Neutral Sentiment: Full earnings materials and call transcripts/slide deck are available for deeper analysis (useful for active investors deciding if the EPS miss changes the growth story). Earnings transcript
• Negative Sentiment: Bank of America cut its target to $28 and moved to “underperform” (roughly in line with the current level), a bearish signal that can pressure sentiment and reduce conviction among institutional holders. Bank of America note
• Negative Sentiment: Truist lowered its rating to “hold,” signaling more cautious institutional views after the quarter. Truist rating change
• Negative Sentiment: UBS trimmed its target to $36 and moved to “neutral” — another downward revision that reduces consensus upside and may weigh on momentum. UBS note
• Negative Sentiment: Analyst and market commentary is highlighting legal and generic risks around WAKIX; these longer-term downside scenarios are being re-priced by some investors. Yahoo coverage on legal/generic risks

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.